Biochemical markers of myocardial remodelling in hypertensive heart disease

Cardiovascular Research

Volumn 81, Issue 3, 2009, Pages 509-518

  González, Arantxa ^a   López, Begoña ^a   Ravassa, Susana ^a   Beaumont, Javier ^a   Arias, Teresa ^a   Hermida, Nerea ^a   Zudaire, Amaia ^a   Díez, Javier ^a,b,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Annexin A5; Biochemical markers; Cardiotrophin 1; Hypertension; Metalloproteinase 1; PICP; Tissue inhibitor of metalloproteinases 1

Indexed keywords

BIOCHEMICAL MARKER; CARDIOTROPHIN 1; INTERSTITIAL COLLAGENASE; LIPOCORTIN 5; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE;

CLINICAL ASSESSMENT; CLINICAL FEATURE; DECISION MAKING; ELECTRIC POTENTIAL; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; IMAGING; INFORMATION; MOLECULE; PRIORITY JOURNAL; REVIEW; STRATIFICATION;

ANIMALS; ANNEXIN A5; APOPTOSIS; BIOLOGICAL MARKERS; CARDIOMEGALY; COLLAGEN; CYTOKINES; DISEASE PROGRESSION; HEART FAILURE; HUMANS; HYPERTENSION; MATRIX METALLOPROTEINASE 1; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR REMODELING;

EID: 59449103786     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn235     Document Type: Review

References (85)

1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-1562.
2. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol 1987;10(Suppl. 6):S135-S140.
3. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 2008;26:1477-1486.
4. Díez J, González A, López B, Querejeta R. Mechanisms of disease: pathologic structural remodelling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2005;2:209-216.
5. Swynghedauw B. Molecular mechanisms of myocardial remodelling. Physiol Rev 1999;79:215-262.
6. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-2362.
7. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115:949-952.
8. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997;59:551-571.
9. Kuwahara K, Saito Y, Harada M, Ishikawa M, Ogawa E, Miyamoto Y et al. Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation 1999;100:1116-1124.
10. Sano M, Fukuda K, Kodama H, Takahashi T, Kato T, Kahuno D et al. Interleukin-6 family of cytokines causes angiotensin II-induced delayed STAT3 activation. Biochem Biophys Res Commun 2000;269:798-802.
11. Pennica D, Wood WI, Chien KR. Cardiotrophin-1: a multifunctional cytokine that signals via LIF receptor-gp 130 dependent pathways. Cytokine Growth Factor Rev 1996;7:81-91.
12. López N, Díez J, Fortuño MA. Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. J Mol Cell Cardiol 2006;41:902-913.
13. Zolk O, Engmann S, Münzel F, Krajcik R. Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. Am J Physiol Endocrinol Metab 2005;288:E1214-E1221.
14. Ishikawa M, Saito Y, Miyamoto Y, Kuwahara K, Ogawa E, Nakagawa O et al. cDNA cloning of cardiotrophin-1 (CT-1): augmented expression of CT-1 gene in ventricle of genetically hypertensive rats. Biochem Biophys Res Commun 1996;219:377-381.
15. Ishikawa M, Saito Y, Miyamoto Y, Harada M, Kuwahara K, Ogawa E et al. A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. J Hypertens 1999;17:807-816.
16. López N, Varo N, Díez J, Fortuño MA. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? Cardiovasc Res 2007;75:536-545.
17. Asai S, Saito Y, Kuwahara K, Mizuno Y, Yoshimura M, Higashikubo C et al. The heart is a source of circulating cardiotrophin-1 in humans. Biochem Biophys Res Commun 2000;279:320-323.
18. González A, Ravassa S, Loperena I, López B, Beaumont J, Querejeta R et al. Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J Hypertens 2007;25:2148-2157.
19. López B, González A, Lasarte JJ, Sarobe P, Borrás F, Díaz A et al. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens 2005;23:625-632.
20. Pemberton CJ, Raudsepp SD, Yandle TG, Cameron VA, Richards AM. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res 2005;68:109-117.
21. González A, López B, Martín-Raymondi D, Lozano E, Varo N, Barba J et al. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens 2005;23:2297-2304.
22. de Simone G, Devereux RB, Kimball TR, Mureddu GF, Roman MJ, Contaldo F et al. Interaction between body size and cardiac workload influence on left ventricular mass during body growth and adulthood. Hypertension 1998;31:1077-1082.
23. López B, Castellano JM, González A, Barba J, Díez J. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension 2007;50:977-983.
24. González A, Fortuño MA, Querejeta R, Ravassa S, López B, López N et al. Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res 2003;59:549-562.
25. 2+ influx regulates growth plate chondrocyte maturation and apoptosis. J Biol Chem 2003;278:3762-3769.
26. Konishi Y, Sato H, Tanaka T. Anisomycin superinduces annexin V mRNA expression through the ERK1/2 but not the p38 MAP kinase pathway. Biochem Biophys Res Commun 2004;313:977-983.
27. Monceau V, Belikova Y, Kratassiouk G, Charue D, Camors E, Communal C et al. Externalization of endogenous annexin A5 participates in apoptosis of rat cardiomyocytes. Cardiovasc Res 2004;64:496-506.
28. 2+ handling in the heart. Cardiovasc Res 2005;65:793-802.
29. Trouvé P, Legot S, Bélikova I, Marotte F, Bénévolensky D, Russo-Marie F et al. Localization and quantitation of cardiac annexins II, V, and VI in hypertensive guinea pigs. Am J Physiol 1999;276:H1159-H1166.
30. Ravassa S, González A, López B, Beaumont J, Querejeta R, Larman M et al. Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. Eur Heart J 2007;28:2785-2791.
31. Benevolensky D, Belikova Y, Mohammadzadeh R, Trouvé P, Marotte F, Russo-Marie F et al. Expression and localization of the annexins II, V, and VI in myocardium from patients with end-stage heart failure. Lab Invest 2000;80:123-133.
32. Song G, Campos B, Wagoner LE, Dedman JR, Walsh RA. Altered cardiac annexin mRNA and protein levels in the left ventricle of patients with end-stage heart failure. J Mol Cell Cardiol 1998;30:443-451.
33. Laufer EM, Reutelingsperger CP, Narula J, Hofstra L. Annexin A5: an imaging biomarker of cardiovascular risk. Basic Res Cardiol 2008;103:95-104.
34. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000;15:264-272.
35. Díez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens 2007;9:546-550.
36. Díez J, Panizo A, Gil MJ, Monreal I, Hernandez M, Pardo Mindan J. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation 1996;93:1026-1032.
37. Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC et al. Serum carboxy-terminal propeptide procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000;101:1729-1735.
38. López B, Querejeta R, Varo N, González A, Larman M, Martínez Ubago JL et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001;104:286-291.
39. López B, González A, Beaumont J, Querejeta R, Larman M, Díez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007;50:859-867.
40. Querejeta R, López B, González A, Sanchez E, Larman M, Martinez Ubago JL et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin. Relation to myocardial fibrosis. Circulation 2004;110:1263-1268.
41. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-dependent regression of myocardial fibrosis and improvement of left ventricular chamber stiffness in hypertensive patients. Circulation 2002;105:2512-2517.
42. Díez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995;91:1450-1456.
43. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-2035.
44. Laviades C, Varo N, Díez J. Transforming growth factor beta in hypertensives with cardio-renal damage. Hypertension 2000;36:517- 522.
45. McNulty, Mahmud A, Spiers P, Feely J. Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects. J Hum Hypertens 2006;20:867-873.
46. Müller-Brunotte R, Kahan T, López B, Edner M, González A, Díez J et al. Myocardial fibrosis and diastolic dysfunction in patients with hipertensión: results from Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens 2007;25:1958-1966.
47. Ling YH, Shiau YC, Yen RF, Lin LC, Wu CC, Ho YL et al. The relation between myocardial cyclic variations of integrated backscatter and serum concentrations of procollagen propeptides in hypertensives patients. Ultrasound Med Biol 2004;30:885-891.
48. Martos R, Baugh J, Ledwige M, ÓLoughlin C, Conlon C, Patle A et al. Evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007;115:888-895.
49. Lee S, Solow-Cordero DE, Kessler E, Takahara K, Greenspan DS. Transforming growth factor-β regulation of bone morphogenetic protein-1/procollagen C-proteinase and related proteins in fibrogenic cells and keratinocytes. J Biol Chem 1997;272:19059-19066.
50. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodelling and regulatory mechanisms. J Mol Cell Cardiol 1994;26:279-292.
51. Janicki JS, Brower GL. The role of myocardial fibrillar collagen in ventricular remodelling and function. J Card Fail 2002;8(suppl.): S319-S325.
52. Linzbach AJ. Hypertrophy, hyperplasia and structural dilatation of the human heart. Adv Cardiol 1976;18:1-14.
53. Baicu CF, Stroud JD, Livesay VA, Hapke E, Holder J, Spinale FG et al. Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol 2003;284:H122-H132.
54. Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 2000;106:857-866.
55. Coker ML, Doscher MA, Thomas CV, Galis ZS, Spinale FG. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol Heart Circ Physiol 1999;277:H777-H787.
56. López B, González A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006;48:89-96.
57. Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998;98:535-540.
58. Tsutamoto T, Asai S, Tanaka T, Sakai H, Nishiyama K, Fujii M et al. Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure. Eur J Heart Fail 2007;9:1032-1037.
59. Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N terminal probrain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 2000;84:421-424.
60. Talwar S, Squire IB, O'Brien RJ, Downie PF, Davies JE, Ng LL. Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction. Clin Sci (Lond) 2002;102:9-14.
61. Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL. Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction. J Card Fail 2006;12:635-640.
62. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001;38:1485-1490.
63. Talwar S, Downie PF, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 2001;3:15-19.
64. Kaneko N, Matsuda R, Hosoda S, Kajita T, Ohta Y. Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction. Clin Chim Acta 1996;251:65-80.
65. Matsuda R, Kaneko N, Kikuchi M, Chiwaki F, Toda M, Ieiri T et al. Clinical significance of measurement of plasma annexin V concentration of patients in the emergency room. Resuscitation 2003;57:171-177.
66. Takino T, Nakamura M, Hiramori K. Circulating levels of carboxyterminal propeptide of type I procollagen and left ventricular remodelling after myocardial infarction. Cardiology 1999;91:81-86.
67. Poulsen SH, Høst NB, Egstrup K. Long-term changes in collagen formation expressed by serum carboxyterminal propeptide of type-I procollagen and relation to left ventricular function after acute myocardial infarction. Cardiology 2001;96:45-50.
68. Cerisano G, Pucci PD, Sulla A, Tommasi M, Raspanti S, Santoro GM et al. Relation between plasma brain natriuretic peptide, serum indexes of collagen type I turnover, and left ventricular remodelling after reperfused acute myocardial infarction. Am J Cardiol 2007;99:651-656.
69. McGavigan AD, Maxwell PR, Dunn FG. Serological evidence of altered collagen homeostasis reflects early ventricular remodelling following acute myocardial infarction. Int J Cardiol 2006;111:267-274.
70. Murakami T, Kusachi S, Murakami M, Sano I, Uesugi T, Hirami R et al. Time-dependent changes of serum carboxy-terminal peptide of type I procollagen and carboxy-terminal telopeptide of type I collagen concentrations in patients with acute myocardial infarction after successful reperfusion: correlation with left ventricular volume indices. Clin Chem 1998;44:2453-2461.
71. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 2002;4:439-444.
72. Fassbach M, Schwartzkopff B. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol 2005;94:328-335.
73. Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 2003;108:1455-1460.
74. Ihm SH, Youn HJ, Shin DI, Jang SW, Park CS, Kim PJ et al. Serum carboxyterminal propeptide of type I procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. Int J Cardiol 2007;122:e36-e38.
75. Papadopoulos DP, Moyssakis I, Makris TK, Poulakou M, Stavroulakis G, Perrea D et al. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction. Eur Cytokine Netw 2005;16:152-160.
76. Ueshima K, Shibata M, Suzuki T, Endo S, Hiramori K. Extracellular matrix disturbances in acute myocardial infarction: relation between disease severity and matrix metalloproteinase-1, and effects of magnesium pretreatment on reperfusion injury. Magnes Res 2003;16:120-126.
77. Picano E, Pelosi G, Marzilli M, Lattanzi F, Benassi A, Landini L et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990;81:58-64.
78. Ciulla M, Paliotti R, Hess DB, Tjahja E, Campbell SE, Magrini F et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997;10:657-664.
79. Maceira AM, Barba J, Varo N, Beloqui O, Díez J. Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. Hypertension 2002;39:923-928.
80. Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 2005;45:98-103.
81. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43:2260-2264.
82. Kietselaer BL, Reutelingsperger CP, Boersma HH, Heidendal GA, Liem IH, Crijns HJ et al. Noninvasive detection of programmed cell loss with 99mTc-labeled annexin A5 in heart failure. J Nucl Med 2007;48:562-567.
83. Díez J, Laviades C, Orbe J, Zalba G, López B, González A et al. The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J Hypertens 2003;21:2085-2092.
84. Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 2006;48:1733-1741.
85. Berhane BT, Zong C, Liem DA, Huang A, Le S, Edmondson RD et al. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 2005;5:3520-3530.